Latest Breaking News On - Publication only - Page 2 : comparemela.com

Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared. | June 3, 2023

United statesRancho mirageCastle bioscienceCastle biosciencesDavid hyamsNational comprehensive cancer networkCastle biosciences incNational cancer instituteAmerican society of clinical oncologyHealth services researchProgram registriesAmerican joint committee on cancerClinical oncologyAnnual meetingDesert surgical oncologyPoster session

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.

United statesRodney varnerMark bergerAmerican society of clinical oncologyGenprex incPrnewswire genprex incCompany websiteExchange commissionDrug administrationResults show combinationWell toleratedAll three dose levelsEncouraging evidenceImmunogene therapyClinical oncologyAnnual meeting

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKalyn dabbsRodney varnerMark bergerAmerican society of clinical oncologyDrug administrationPrnewswire genprex incExchange commissionCompany websiteGenprex incResults show combinationWell toleratedAll three dose levelsEncouraging evidenceImmunogene therapyClinical oncology

Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings

Wide range of research across tumor types underscores Servier s commitment to discovering novel approaches to addressing difficult-to-treat cancers Phase 3.

United statesClaudep bertrandPrnewswire servierDavidk leeBristol myers squibbD andrew sallmanSonia marquesJulia ferreiraAmerican society of clinical oncologyTaiho pharmaceutical co ltdServier group franceDrug administrationEuropean hematology associationServier groupAmerican society of hematologyServier pharmaceuticals

Dxcover Limited: Dxcover to Release New Data on Early Detection Liquid Biopsy for Multiple Cancer Types at 2022 ASCO Annual Meeting

Dxcover Limited, a clinical stage diagnostics company developing its spectroscopic biopsy technology for early detection of multiple cancers, today announced that it will be presenting new data at

United kingdomUnited statesKostenloser wertpapierhandelMatthewj bakerTara mulloyAmerican society of clinical oncologyDxcover limitedClinical oncologyAnnual meetingChief technology officerTumor biologyPoster discussion sessionGastrointestinal cancer gastroesophagealPublication only